Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: In vitro and in vivo studies

Nanomedicine

Volumn 7, Issue 12, 2012, Pages 1839-1849

  Costa Lima, Sofia A ^a   Resende, Mariana ^a   Silvestre, Ricardo ^a   Tavares, Joana ^a,b   Ouaissi, Ali ^a,c   Lin, Paul Kong Thoo ^d   Cordeiro Da Silva, Anabela ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIV MONTPELLIER   (France)

^d ROBERT GORDON UNIVERSITY   (United Kingdom)

Author keywords

BALB c mice; bisnaphthalimidopropyldiaaminooctane; in vivo visceral leishmaniasis; macrophages; PLGA nanoparticles

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTILEISHMANIAL AGENT; BISNAPHTHALIMIDOPROPYLDIAAMINOOCTANE; NANOPARTICLE; NAPHTHALIMIDE DERIVATIVE; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISPERSION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS; ZETA POTENTIAL;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; DRUG CARRIERS; HUMANS; LACTIC ACID; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; NANOPARTICLES; NAPHTHALIMIDES; POLYGLYCOLIC ACID;

EID: 84871263911     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.74     Document Type: Article

References (23)

1. Romero EL, Morilla MJ. Drug delivery systems against leishmaniasis? Still an open question. Expert Opin. Drug Deliv. 5, 805-823 (2008).
2. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5, 873-882 (2007).
3. Berman J. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin. Drug Metab. Toxicol. 4, 1209-1216 (2008).
4. Sundar S, Jha T, Thakur C, Sinha P, Bhattacharya S. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 356, 2571-2581 (2007).
5. Croft S, Olliaro P. Leishmaniasis chemotherapy - challenges and opportunities. Clin. Microbiol. Infect. 17, 1478-1483 (2011).
6. Oliveira J, Ralton L, Tavares J et al. The synthesis and the in vitro cytotoxicity studies of bisnaphthalimidopropyl polyamine derivatives against colon cancer cells and parasite Leishmania infantum. Bioorg. Med. Chem. 15, 541-545 (2007).
7. Tavares J, Ouaissi A, Lin PK, Tomas A, Cordeiro-da-Silva A. A differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes. Int. J. Parasitol. 35, 637-646 (2005).
8. Ritter U, Frischknecht F, Zandbergen GV. Are neutrophils important host cells for Leishmania parasites? Trends Parasitol. 25, 505-510 (2009).
9. Bogdan C, Donhauser N, Döring R, Röllinghoff M, Diefenbach A, Rittig MG. Fibroblasts as host cells in latent leishmaniosis. J. Exp. Med. 191, 2121-2130 (2000).
10. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23, 1411-1450 (2006).
11. Lala S, Gupta S, Sahu NP et al. Critical evaluation of the therapeutic potential of bassic acid incorporated in oil-in-water microemulsions and poly-d,l-lactide nanoparticles against experimental leishmaniasis. J. Drug Target. 14, 171-179 (2006).
12. Espuelas MS, Legrand P, Loiseau PM et al. In vitro antileishmanial activity of amphotericin B loaded in poly(e-caprolactone) nanospheres. J. Drug Target. 10, 593-599 (2002).
13. Nahar M, Jain NK. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm. Res. 26, 2588-2598 (2009).
14. Tavares J, Ouaissi A, Silva A et al. Anti-leishmanial activity of the bisnaphthalimidopropyl derivatives. Parasitol. Int. 61, 360-363 (2012).
15. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55, R1-R4 (1989).
16. Silvestre R, Silva AM, Cordeiro-da-Silva A, Ouaissi A. The contribution of toll-like receptor 2 to the innate recognition of a Leishmania infantum silent information regulator 2 protein. Immunology 128, 484-499 (2009).
17. Kadam RU, Tavares J, Kiran V et al. Structure function analysis of Leishmania sirtuin: an ensemble of in silico and biochemical studies. Chem. Biol. Drug Des. 71, 501-506 (2008).
18. Buffet PA, Sulahian A, Garin YJ, Nassar N, Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39, 2167-2168 (1995).
19. Berne BJ, Pecora R. Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics. Dover Publications, NY, USA (2000).
20. Pulkkinen M, Pikkarainen J, Wirth T et al. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: formulation development and in vitro anticancer activity. Eur. J. Pharm. Biopharm. 70, 66-74 (2008).
21. Coppi G, Montanari M, Rossi T, Bondi M, Iannuccelli V. Cellular uptake and toxicity of microparticles in a perspective of polymyxin B oral administration. Int. J. Pharm. 385, 42-46 (2010).
22. Li Q, Liu C, Zhao X et al. Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells. Int. J. Nanomed. 6, 397-405 (2011).
23. Tavares J, Ouaissi A, Kong Thoo Lin P et al. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. Chem. Med. Chem. 5, 140-147 (2009).